Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

NCT03892525 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped End of drug development

Conditions

Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma

Interventions

DRUG: Selicrelumab
DRUG: Atezolizumab

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]